National Academies Press: OpenBook

Making Medicines Affordable: A National Imperative (2017)

Chapter: Appendix B A Minority Perspective

« Previous: Appendix A A Dissenting View
Suggested Citation:"Appendix B A Minority Perspective." National Academies of Sciences, Engineering, and Medicine. 2017. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
Page 165
Suggested Citation:"Appendix B A Minority Perspective." National Academies of Sciences, Engineering, and Medicine. 2017. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
Page 166
Suggested Citation:"Appendix B A Minority Perspective." National Academies of Sciences, Engineering, and Medicine. 2017. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
Page 167
Suggested Citation:"Appendix B A Minority Perspective." National Academies of Sciences, Engineering, and Medicine. 2017. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
Page 168

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

B A Minority Perspective Rena Conti, Stacie Dusetzina, Martha Gaines, Rebekah Gee, Victoria Hale, Peter Sands, and Alan Weil The charge to this committee was to “address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.” The recommendations in the report are an important step in this direction. We endorse them. However, they do not go far enough. To fulfill our charge of providing recommendations that will ensure access to affordable drugs, we need more ambitious approaches to transparency, value assessments, and pricing. The committee’s report shines a powerful spotlight on the myriad ways in which actors within the biopharmaceutical development, production, and distribution system exploit information asymmetries, misaligned incentives and market power to maximize profits, often to the detriment of individual patients or society as a whole. Even as the biopharmaceutical industry delivers enormous benefits through the development of new drugs with significant clinical value, the shortcomings of our current approach are apparent. Too many patients cannot afford the drugs they need. The committee’s recommendations take a piecemeal approach to addressing specific flaws in the current system. These changes, if adopted, will remove some market distortions, but will leave many others in place that will continue to be exploited to the detriment of patients. To achieve a more patient-centric system, we need a more comprehensive approach. Making the biopharmaceutical market work for patients The report claims that “an inherent conflict exists between the desire of patients … for affordable drugs and the expectations of … biopharmaceutical companies for a competitive return on investment.” Framing the problem this way leads to a false choice between affordable access to patients and reasonable financial rewards to biopharmaceutical companies. We reject this premise. By contrast, we believe a well-functioning biopharmaceutical market is precisely what is needed to achieve the committee’s charge. The current biopharmaceutical market displays so many market failures and distortions that marginal improvements in market functioning will be insufficient to achieve the goal of affordable drugs. Taking the view that the method for achieving patient access to affordable drugs is to redesign the regulatory framework that defines the market, we identify three specific areas where the committee’s recommendations should be stronger. They are in the areas of transparency, value assessments, and pricing. 167 PREPUBLICATION COPY: UNCORRECTED PROOFS

MAKING MEDICINES AFFORDABLE 168 Transparency Markets only function effectively when customers have choices: They can switch to another product, or buy nothing. In the biopharmaceutical market, formularies are the mechanism for making these choices. Yet the current approach to the design and operation of formularies has two significant flaws. First, there is little transparency regarding how formularies are developed. Clinical considerations are paramount, but the methods by which formulary developers make clinical judgments are unknown to the patient. The degree to which financial interests affect choices by pharmacy benefit managers is also unknown. Second, because many formularies, particularly in government-sponsored programs, are legally or effectively precluded from excluding drugs, they rely heavily on tiering: applying different levels of cost-sharing to different drugs. Patients cannot exert any force in the market when they are given a price with no relevant information to evaluate their choices. The committee’s transparency recommendations focus on financial flows among manufacturers, intermediaries in the supply chain, clinicians, hospitals and payers. But transparency regarding the criteria used to determine coverage, pricing, and formulary decisions is also critical. In a market with high levels of information asymmetry and where patients are heavily affected by decisions made by professionals and systems that are opaque to them, payers and other intermediaries should be required to disclose the methods they use to design and manage formularies and to reveal where and how their decisions relate to their own financial interests. Value Assessments Purchasers in a marketplace make choices based upon the value they place on the products they are buying. In other advanced economies, value-based assessment of drugs is seen as a vital tool in formulary design and drug price negotiations. Decisions around coverage, prices, and formulary inclusion are made on the basis of formal assessments of efficacy, comparative effectiveness and value relative to cost. In the United States, formal adoption of value-based approaches is hampered by legitimate disagreements regarding how to measure value compounded by political concerns regarding anything perceived to be rationing care. Yet, since all purchasers must make their decisions on the basis of something, the result is opaque and obscure practices with implicit value assessments that cannot be subject to scrutiny by patients and their clinicians. So long as the methods purchasing intermediaries, hospitals and payers use to make coverage, pricing, and formulary decisions are opaque, patients and policymakers cannot know whether current arrangements provide value that outweighs the costs to patients and the health care system. The committee appropriately recommends further testing and refinement of methods for determining the “value” of drugs and using those methods in formulary design and payment policy. This recommendation understates the maturity of those methods as used around the world today and by American payers, intermediaries, physicians and hospital systems. Its tentative tone belies the reality that, in the absence of such methods, patients are left at the mercy of coverage and pricing decisions that are completely unknown to them. To make the market more patient-oriented, public and PREPUBLICATION COPY: UNCORRECTED PROOFS

MAKING MEDICINES AFFORDABLE 169 private purchasers should adopt value assessment methods, use them systematically, and make them transparent. Pricing Our committee chair points out in his preface that drugs that do not exist are of no value. This view captures the importance of sustaining incentives for innovation. Yet the committee’s report does not go far enough in considering how the current drug pricing regime distorts both the incentives for investment in research and development and the way the drugs are deployed once launched. Current mechanisms for setting drug prices can yield prices that are either too high or too low for achieving optimal public health or optimal investments in innovations that promote public health. Many drugs, particularly for infectious diseases, create significant positive externalities (improving the health of others) that are not built into the price. Manufacturers set prices in part based upon ability to pay, which is highly variable depending upon whether the patient has private insurance, public coverage, or is uninsured, even though the disease burden is not evenly distributed across these populations. Our current system can lead to underinvestment in drugs with substantial public health benefits, such as vaccines, and under-deployment of such drugs when they are developed, as we have seen with therapies that cure Hepatitis C. By contrast, the current system creates powerful incentives to invest in research and development in drugs for people with good health insurance even where the incremental value relative to existing therapies is limited. Direct government funding and purchasing can cure some of the distortions in investment and deployment. Yet, public resources are limited and it is more efficient to harness the power of the market to achieve these social goals. A recent National Academies study explores alternative public purchasing models for Hepatitis C drugs with the goals of increased access and affordability.51 The committee appropriately recommends exploration of alternative payment models. Yet once again the committee’s general language downplays what is at stake. Robust value assessments, which include consideration of patient-defined outcomes and public health consequences, should be used when establishing or negotiating drug prices. Such an approach would build in market incentives for actions that guide investment in innovation and the deployment of developed drugs towards improving population health. Conclusion We reiterate our support for the committee’s recommendations. However, we believe the committee could and should have gone farther in strengthening and expanding our recommendations to achieve the goals set out in our charge. A more patient-centric biopharmaceutical sector that provides access to affordable drugs is within the nation’s reach. 51 NASEM. 2017. A national strategy for the elimination of hepatitis B and C: Phase two report. Washington, DC: The National Academies Press. PREPUBLICATION COPY: UNCORRECTED PROOFS

Next: Appendix C Glossary »
Making Medicines Affordable: A National Imperative Get This Book
Buy Paperback | $65.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicines—and health care at large—more affordable for everyone has become a socioeconomic imperative.

Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual’s insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugs—coupled with the broader trends in overall health care costs—is unsustainable to society as a whole.

Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook,'s online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!